NSCLC is one solid tumor where comprehensive genomic profiling can dramatically alter precision-based strategy. Can you give an example where the detection of a rare insertion altered treatment?

NSCLC is one solid tumor where comprehensive genomic profiling can dramatically alter precision-based strategy. Can you give an example where the detection of a rare insertion altered treatment?

As you explained, NSCLC is one solid tumor where comprehensive genomic profiling can dramatically alter a precision-based strategy. Can you provide a patient example where you have observed that the detection of a rare insertion altered the treatment choice?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Prof. Matthew Krebs, MD, PhD

Prof. Matthew Krebs, MD, PhD

Clinical Senior Lecturer
Experimental Cancer Medicine
Honorary Consultant
Medical Oncology
The University of Manchester
Greater Manchester, UK